Tiziana Life Sciences Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSA research report →
Companywww.tizianalifesciences.com
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
- CEO
- Ivor R. Elrifi
- IPO
- 2018
- Employees
- 9
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $89.14M
- P/E
- -4.11
- P/S
- 0.00
- P/B
- 2.35
- EV/EBITDA
- 2.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -125.84%
- ROIC
- -41.20%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-18,431,000 · -55.37%
- EPS
- $-0.32 · -45.45%
- Op Income
- $-21,284,000
- FCF YoY
- -942.29%
Performance & Tape
- 52W High
- $2.60
- 52W Low
- $1.14
- 50D MA
- $1.31
- 200D MA
- $1.63
- Beta
- 0.42
- Avg Volume
- 153.30K
Get TickerSpark's AI analysis on TLSA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | CERRONE GABRIELE M | other | 0 |
| Mar 18, 26 | CERRONE GABRIELE M | other | 1,629,702 |
| May 3, 28 | CERRONE GABRIELE M | other | 250,000 |
Our TLSA Coverage
We haven't published any research on TLSA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TLSA Report →